Vaccentis names Martin Munte as CEO and strengthens board

Swiss clinical-stage biotech Vaccentis, which is developing patient-specific medicines, today announced the appointment of Martin Munte, a veteran leader in biotech and pharma, with extensive executive experience from Amgen, (Nasdaq: AMGN) AstraZeneca (LSE: AZN) and Roche (ROG: SIX), as its new chief executive.

Martin Munte held a series of senior roles at Amgen for 12 years, most recently as external access engagement lead Europe. He previously held management positions at both AstraZeneca and Roche. He has strong expertise as a leader in general management, sales and marketing, policy, access, regulatory and business development.

The appointment further strengthens Vaccentis’ leadership team, following the appointment of three high-profile entrepreneurs, Matthias Oertle, Marcel Frei and Subhasis Roy, as members of a five-person board of directors in May, with Matthias Oertle serving as chairman.